1qjy
From Proteopedia
| Line 4: | Line 4: | ||
|PDB= 1qjy |SIZE=350|CAPTION= <scene name='initialview01'>1qjy</scene>, resolution 2.8Å | |PDB= 1qjy |SIZE=350|CAPTION= <scene name='initialview01'>1qjy</scene>, resolution 2.8Å | ||
|SITE= <scene name='pdbsite=MYR:Myristylation+Is+Observed+At+N-Terminus+Of+Vp4,+Which+Li+...'>MYR</scene>, <scene name='pdbsite=POC:An+Antiviral+Compound+Is+Found+In+A+Pocket+Of+Vp1'>POC</scene>, <scene name='pdbsite=RNA:RNA+Observed+Interacting+w.+These+Residues+On+Interior+S+...'>RNA</scene> and <scene name='pdbsite=ZN:Putative+Zn+Binding+Site+On+Icosahedral+Five-Fold+Axis.+...'>ZN</scene> | |SITE= <scene name='pdbsite=MYR:Myristylation+Is+Observed+At+N-Terminus+Of+Vp4,+Which+Li+...'>MYR</scene>, <scene name='pdbsite=POC:An+Antiviral+Compound+Is+Found+In+A+Pocket+Of+Vp1'>POC</scene>, <scene name='pdbsite=RNA:RNA+Observed+Interacting+w.+These+Residues+On+Interior+S+...'>RNA</scene> and <scene name='pdbsite=ZN:Putative+Zn+Binding+Site+On+Icosahedral+Five-Fold+Axis.+...'>ZN</scene> | ||
| - | |LIGAND= | + | |LIGAND= <scene name='pdbligand=MYR:MYRISTIC+ACID'>MYR</scene>, <scene name='pdbligand=W03:2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[2-METHYL-4-ISOXAZOLYL]-PHENOL'>W03</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene> |
|ACTIVITY= | |ACTIVITY= | ||
|GENE= | |GENE= | ||
| + | |DOMAIN= | ||
| + | |RELATEDENTRY= | ||
| + | |RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1qjy FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1qjy OCA], [http://www.ebi.ac.uk/pdbsum/1qjy PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=1qjy RCSB]</span> | ||
}} | }} | ||
| Line 16: | Line 19: | ||
==About this Structure== | ==About this Structure== | ||
| - | 1QJY is a [[Protein complex]] structure of sequences from [http://en.wikipedia.org/wiki/ | + | 1QJY is a [[Protein complex]] structure of sequences from [http://en.wikipedia.org/wiki/Human_rhinovirus_16 Human rhinovirus 16]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1QJY OCA]. |
==Reference== | ==Reference== | ||
Analysis of three structurally related antiviral compounds in complex with human rhinovirus 16., Hadfield AT, Diana GD, Rossmann MG, Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14730-5. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/10611281 10611281] | Analysis of three structurally related antiviral compounds in complex with human rhinovirus 16., Hadfield AT, Diana GD, Rossmann MG, Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14730-5. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/10611281 10611281] | ||
| - | [[Category: Human rhinovirus | + | [[Category: Human rhinovirus 16]] |
[[Category: Protein complex]] | [[Category: Protein complex]] | ||
[[Category: Diana, G.]] | [[Category: Diana, G.]] | ||
[[Category: Hadfield, A T.]] | [[Category: Hadfield, A T.]] | ||
[[Category: Rossmann, M G.]] | [[Category: Rossmann, M G.]] | ||
| - | [[Category: MYR]] | ||
| - | [[Category: W03]] | ||
| - | [[Category: ZN]] | ||
[[Category: antiviral compound]] | [[Category: antiviral compound]] | ||
[[Category: drug]] | [[Category: drug]] | ||
| Line 35: | Line 35: | ||
[[Category: win compound]] | [[Category: win compound]] | ||
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Mar 30 23:14:43 2008'' |
Revision as of 20:14, 30 March 2008
| |||||||
| , resolution 2.8Å | |||||||
|---|---|---|---|---|---|---|---|
| Sites: | , , and | ||||||
| Ligands: | , , | ||||||
| Resources: | FirstGlance, OCA, PDBsum, RCSB | ||||||
| Coordinates: | save as pdb, mmCIF, xml | ||||||
HUMAN RHINOVIRUS 16 COAT PROTEIN IN COMPLEX WITH ANTIVIRAL COMPOUND VP65099
Overview
Rhinoviruses are a frequent cause of the common cold. A series of antirhinoviral compounds have been developed that bind into a hydrophobic pocket in the viral capsid, stabilizing the capsid and interfering with cell attachment. The structures of a variety of such compounds, complexed with rhinovirus serotypes 14, 16, 1A, and 3, previously have been examined. Three chemically similar compounds, closely related to a drug that is undergoing phase III clinical trials, were chosen to determine the structural impact of the heteroatoms in one of the three rings. The compounds were found to have binding modes that depend on their electronic distribution. In the compound with the lowest efficacy, the terminal ring is displaced by 1 A and rotated by 180 degrees relative to the structure of the other two. The greater polarity of the terminal ring in one of the three compounds leads to a small displacement of its position relative to the other compounds in the hydrophobic end of the antiviral compound binding pocket to a site where it makes fewer interactions. Its lower efficacy is likely to be the result of the reduced number of interactions. A region of conserved residues has been identified near the entrance to the binding pocket where there is a corresponding conservation of the mode of binding of these compounds to different serotypes. Thus, variations in residues lining the more hydrophobic end of the pocket are primarily responsible for the differences in drug efficacies.
About this Structure
1QJY is a Protein complex structure of sequences from Human rhinovirus 16. Full crystallographic information is available from OCA.
Reference
Analysis of three structurally related antiviral compounds in complex with human rhinovirus 16., Hadfield AT, Diana GD, Rossmann MG, Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14730-5. PMID:10611281
Page seeded by OCA on Sun Mar 30 23:14:43 2008
